Menu
Search
|

Menu

Close
X

Adamas Pharmaceuticals Inc ADMS.OQ (NASDAQ Stock Exchange Global Market)

27.41 USD
-- (--)
As of 2:29 AM IST
chart
Previous Close 27.41
Open --
Volume --
3m Avg Volume 296,226
Today’s High --
Today’s Low --
52 Week High 43.98
52 Week Low 13.51
Shares Outstanding (mil) 22.51
Market Capitalization (mil) 520.30
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.78 Mean rating from 9 analysts

KEY STATS

Revenue (mm, USD)
FY17
0
FY16
1
FY15
2
EPS (USD)
FY17
-2.683
FY16
-2.766
FY15
-2.862
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
32.90
Price to Sales (TTM)
vs sector
2,939.55
5.77
Price to Book (MRQ)
vs sector
5.00
5.41
Price to Cash Flow (TTM)
vs sector
--
23.42
Total Debt to Equity (MRQ)
vs sector
32.50
16.52
LT Debt to Equity (MRQ)
vs sector
32.50
12.22
Return on Investment (TTM)
vs sector
-44.88
14.43
Return on Equity (TTM)
vs sector
-51.05
16.13

EXECUTIVE LEADERSHIP

Gregory Went
Chairman of the Board, Chief Executive Officer, Co-Founder, Since 2000
Salary: $450,000.00
Bonus: $250,000.00
Alfred Merriweather
Chief Financial Officer, Since 2017
Salary: --
Bonus: --
Richard King
Chief Operating Officer, Since 2017
Salary: --
Bonus: --
Leonie McConville
Senior Vice President - Human Resources, Since 2016
Salary: --
Bonus: --
Christopher Prentiss
Principal Accounting Officer, Since 2017
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

1900 Powell St Ste 750
EMERYVILLE   CA   94608-2437

Phone: +1510.4503554

Adamas Pharmaceuticals, Inc. is a pharmaceutical company. The Company is engaged in developing medicines to manage the daily lives of those affected by chronic neurologic disorders. It offers a platform based on an understanding of time dependent biologic effects of disease activity and drug response to achieve relief without tolerability issues. It has developed a portfolio of chrono-synchronous therapies to address chronic neurologic disorders. Its first product candidate is ADS-5102, a chrono-synchronous amantadine therapy, for the treatment of levodopa-induced dyskinesia (LID) in patients with Parkinson's disease (PD). It has completed Phase II proof-of-concept study of ADS-5102 in these patients. Its Phase III clinical program included three placebo-controlled trials: EASED, EASE LID and EASE LID 3. Its second product candidate is ADS-4101, an extended-release version of single-agent compound for the treatment of epilepsy (partial onset seizures).

SPONSORED STORIES